Menu Contents

Pipeline

The Research Team at Boryung Pharmaceutical aims to lead the Future of the Pharmaceutical Industry

  • Pipeline Introduction

    After 12 years of research, Boryung Pharmaceutical succeeded in developing the first domestic hypertension drug, ‘Kanarb’. By independently carrying out all the necessary steps – candidate material excavation, raw material synthesis, formulation research, a non-clinical trial, and clinical trial phases one, two and three – Boryung Pharmaceutical has established our very own capability for drug development. Boryung Pharmaceutical was established based on its drug development capabilities. We are expanding our scope of research into a variety of areas to develop drugs for cancer treatment, antibiotics, NCE(New Chemical Entity) and gene therapy that focuses on cardiovascular and other major diseases, vaccines and other biopharmaceuticals. We are particularly focused on the development of the Kanarb Value-Up Pipeline. In addition, we are focusing on the research and development of new API(Active Pharmaceutical Ingredient) products aimed at the globalization of API.

Kanarb Value-up Pipeline

The ‘Kanarb Value-up Pipeline’ consists of products that allow for the integrative treatment of patients with hypertension associated with the majority of metabolic diseases. These products are all NCE and IMDs and developed in-house.
Development of the ‘Kanarb Value-up Pipeline’ will not only increase sales in the single and composite drug market, but will also strengthen the global competitiveness of Kanarb through the global license out.

(March, 2018 standard)

Kanarb Value-up Pipeline
Classification Project Name Treatment for Discovery Pre-clinical Phase 1 Phase 2 Phase 3
IMD BR1006 Hypertension/Dyslipidemia
BR1007 Hypertension/Chronic kidney disease
BR1008 Hypertension/Dyslipidemia
BR1009 Hypertension/Diabetes
BR1010 Hypertension

Kanarb Value-up Pipeline

(March, 2018 standard)

Kanarb Value-up Pipeline
IMD

BR1006

Hypertension/Dyslipidemia

Discovery Pre
clinical
Phase 1 Phase 2 Phase 3

BR1007

Hypertension/Chronic kidney disease

Discovery Pre-
clinical
Phase 1 Phase 2 Phase 3

BR1008

Hypertension/Dyslipidemia

Discovery Pre-
clinical
Phase 1 Phase 2 Phase 3

BR1009

Hypertension/Diabetes

Discovery Pre-
clinical
Phase 1 Phase 2 Phase 3

BR1010

Hypertension

Discovery Pre-
clinical
Phase 1 Phase 2 Phase 3

Pipeline

We are strengthening our R&D portfolio to focus on antibiotics and major diseases such as cancer and cardiovascular disease (CV). We will add a new pipeline that centers on diseases whose markets are expected to grow in the future. We are also focusing on developing NCE and incrementally modified drugs (IMD) to fulfill unmet needs, while working to discover new drugs on the cutting edge of bio-tech.

(March, 2018 standard)

Main Pipeline
Classification Project Name Treatment for Discovery Pre-clinical Phase 1 Phase 2 Phase 3
NCE BR2002 Lymphoma
BR3001 Diabetes
NBE BR2001 Liver cancer(Gene therapy)
IMD BR4001 Alzheimer's disease
BR4002 Alzheimer's disease(Microstructure)
Vaccine BR8002 Dtap-IPV
BR8003 Hepatitis A

Pipeline

(March, 2018 standard)

Main Pipeline
NCE

BR2002

Lymphoma

Discovery Pre-
clinical
Phase 1 Phase 2 Phase 3

BR3001

Diabetes

Discovery Pre-
clinical
Phase 1 Phase 2 Phase 3
NBE

BR2001

Liver cancer(Gene therapy)

Discovery Pre-
clinical
Phase 1 Phase 2 Phase 3
IMD

BR4001

Alzheimer’s disease

Discovery Pre-
clinical
Phase 1 Phase 2 Phase 3

BR4002

Alzheimer's disease(Microstructure)

Discovery Pre-
clinical
Phase 1 Phase 2 Phase 3
vaccine

BR8002

Dtap-IPV

Discovery -
clinical
Phase 1 Phase 2 Phase 3

BR8003

Hepatitis A

Discovery Pre-
clinical
Phase 1 Phase 2 Phase 3
TOP